Matching articles for "Victoza"
Issue 1743 · December 8, 2025 Free
A Cardiovascular Indication for Oral Semaglutide (Rybelsus)

The oral glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide ( Rybelsus – Novo Nordisk), which was approved by the FDA in 2019 for treatment of type 2 diabetes in adults, has now also been approved…

Med Lett Drugs Ther. 2025 Dec 8; 67(1743):195-6 doi:10.58347/tml.2025.1743b
The oral glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide ( Rybelsus – Novo Nordisk), which was approved by the FDA in 2019 for treatment of type 2 diabetes in adults, has now also been approved to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who are at high risk for these events. The injectable GLP-1 receptor agonists semaglutide (Ozempic) , dulaglutide (Trulicity) , and liraglutide (Victoza) are also approved for cardiovascular risk reduction in patients with type 2 diabetes (see Table 1).
Issue 1742 · November 24, 2025
Noninsulin Drugs for Type 2 Diabetes

Diet, exercise, and weight loss can improve glycemic control, but most patients with type 2 diabetes eventually require glucose-lowering pharmacotherapy. An A1C goal of <7% (while minimizing hypoglycemia) is…

Med Lett Drugs Ther. 2025 Nov 24; 67(1742):185-92 doi:10.58347/tml.2025.1742a
Diet, exercise, and weight loss can improve glycemic control, but most patients with type 2 diabetes eventually require glucose-lowering pharmacotherapy. An A1C goal of <7% (while minimizing hypoglycemia) is recommended for most patients to prevent or reduce the microvascular complications of diabetes (retinopathy, nephropathy, neuropathy). An A1C target of <8% may be appropriate for patients who are older, have comorbid conditions, or are at risk of serious hypoglycemia-associated adverse events.
Issue 1742 · November 24, 2025 Free
Comparison Chart: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes (online only)

View the Comparison Chart: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes

Med Lett Drugs Ther. 2025 Nov 24; 67(1742):e195-6 doi:10.58347/tml.2025.1742c
View the Comparison Chart: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
Issue 1742 · November 24, 2025 Free
Comparison Chart: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes (online only)

View the Comparison Chart: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes

Med Lett Drugs Ther. 2025 Nov 24; 67(1742):e195-6 doi:10.58347/tml.2025.1742c
View the Comparison Chart: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
Issue 1734 · August 4, 2025
Drugs and Devices for Weight Management

Overweight is generally defined as a body mass index (BMI) between 25 and 29.9 kg/m 2 in adults. A BMI ≥30 is considered obese (criteria differ slightly in Asian patients). In patients with an elevated BMI,…

Med Lett Drugs Ther. 2025 Aug 4; 67(1734):121-8 doi:10.58347/tml.2025.1734a
Overweight is generally defined as a body mass index (BMI) between 25 and 29.9 kg/m 2 in adults. A BMI ≥30 is considered obese (criteria differ slightly in Asian patients). In patients with an elevated BMI, a 5-10% reduction in weight has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the traditional methods for losing weight, but they are often inadequate; the American College of Cardiology no longer recommends that all patients try lifestyle modification alone before adding pharmacologic treatment for weight loss. Guidelines on pharmacologic treatment of obesity from the American Gastroenterological Association (AGA) were last updated in 2022.
Issue 1723 · March 3, 2025
A Renal Indication for Semaglutide (Ozempic)

The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide ( Ozempic – Novo Nordisk) has been approved by the FDA to reduce the risk of sustained eGFR decline, end-stage kidney disease, and…

Med Lett Drugs Ther. 2025 Mar 3; 67(1723):38-40 doi:10.58347/tml.2025.1723d
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide ( Ozempic – Novo Nordisk) has been approved by the FDA to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD). It is the first GLP-1 receptor agonist to be approved in the US for this indication.
Issue 1718 · December 23, 2024 Free
In Brief: New FDA Warning of Pulmonary Aspiration with GLP-1 Receptor Agonists

The package inserts of the GLP-1 receptor agonists dulaglutide (Trulicity) , exenatide (Byetta, Bydureon BCise) , liraglutide (Saxenda, Victoza) , and semaglutide (Ozempic, Rybelsus, Wegovy) and the dual…

Med Lett Drugs Ther. 2024 Dec 23; 66(1718):201-2 doi:10.58347/tml.2024.1718a
The package inserts of the GLP-1 receptor agonists dulaglutide (Trulicity) , exenatide (Byetta, Bydureon BCise) , liraglutide (Saxenda, Victoza) , and semaglutide (Ozempic, Rybelsus, Wegovy) and the dual glucosedependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) have been updated to include rare postmarketing reports of pulmonary aspiration associated with their use in patients undergoing elective surgery or other procedures requiring general anesthesia or deep sedation who had residual gastric contents despite preoperative fasting.
Issue 1701 · April 29, 2024
A New Indication for Semaglutide (Wegovy)

The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) has been approved by the FDA to reduce the risk of major adverse cardiovascular events (MACE) in adults with established…

Med Lett Drugs Ther. 2024 Apr 29; 66(1701):66-7 doi:10.58347/tml.2024.1701b
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) has been approved by the FDA to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease (CVD) and either obesity or overweight. Semaglutide is the first drug to be approved for cardiovascular risk reduction in this population. It is also approved in a lower-dose injectable formulation as Ozempic and in an oral formulation as Rybelsus (see Table 1).
Issue 1690 · November 27, 2023 Free
In Brief: GI Effects of GLP-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2…

Med Lett Drugs Ther. 2023 Nov 27; 65(1690):191-2 doi:10.58347/tml.2023.1690e
Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2 diabetes and weight management (see Table 1), but they delay gastric emptying and commonly cause nausea and vomiting. Gastroparesis and bowel obstruction (ileus) have also been reported with their use.
Issue 1683 · August 21, 2023 Free
Empagliflozin (Jardiance) for Type 2 Diabetes in Children (online only)

The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin has been available for years alone ( Jardiance – Boehringer Ingelheim) and in combination with metformin (Synjardy) to improve glycemic…

Med Lett Drugs Ther. 2023 Aug 21; 65(1683):e137 doi:10.58347/tml.2023.1683e
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin has been available for years alone ( Jardiance – Boehringer Ingelheim) and in combination with metformin (Synjardy) to improve glycemic control in adults with type 2 diabetes. Both products have now been approved for use in children ≥10 years old. Empagliflozin is the second oral drug to become available in the US for treatment of type 2 diabetes in children; metformin has been available since 2000 for this indication. The injectable glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide (Victoza) and extended-release exenatide (Bydureon BCise) are also approved for use in children ≥10 years old.
Issue 1663 · November 14, 2022
Drugs for Type 2 Diabetes

Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia…

Med Lett Drugs Ther. 2022 Nov 14; 64(1663):177-84
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia is recommended to prevent microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy). An A1C target of <8% may be appropriate for some older patients.
Issue 1654 · July 11, 2022
Tirzepatide (Mounjaro) for Type 2 Diabetes

The FDA has approved tirzepatide ( Mounjaro – Lilly), a peptide hormone with activity at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, to improve…

Med Lett Drugs Ther. 2022 Jul 11; 64(1654):105-7
The FDA has approved tirzepatide ( Mounjaro – Lilly), a peptide hormone with activity at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, to improve glycemic control in adults with type 2 diabetes. Tirzepatide, which is injected subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the US. Selective GIP receptor agonists are not available in the US; GLP-1 receptor agonists have been available for years.
Issue 1584 · November 4, 2019
Drugs for Type 2 Diabetes

Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes eventually require drug therapy. Treating to a glycated hemoglobin (A1C) concentration of <7% can…

Med Lett Drugs Ther. 2019 Nov 4; 61(1584):169-78
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes eventually require drug therapy. Treating to a glycated hemoglobin (A1C) concentration of <7% can prevent microvascular complications (retinopathy, nephropathy, and neuropathy), but whether it prevents macrovascular complications and death is unclear. An A1C target of <8% may be appropriate for older patients and those with underlying cardiovascular disease (CVD), a history of severe hypoglycemia, diabetes-related complications, a limited life expectancy, or a long duration of disease.
Issue 1566 · February 25, 2019
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes

Since 2008, because of safety concerns, the FDA has mandated that long-term cardiovascular outcomes trials be conducted for all new drugs for type 2 diabetes. Reductions in the incidence of macrovascular…

Med Lett Drugs Ther. 2019 Feb 25; 61(1566):26-8
Since 2008, because of safety concerns, the FDA has mandated that long-term cardiovascular outcomes trials be conducted for all new drugs for type 2 diabetes. Reductions in the incidence of macrovascular complications in these trials with some sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists in patients at risk for cardiovascular disease (see Table 1) have led to new recommendations.
Issue 1539 · January 29, 2018
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes

The FDA has approved semaglutide ( Ozempic – Novo Nordisk), a long-acting injectable GLP-1 (glucagon-like peptide-1) receptor agonist, for once-weekly treatment of adults with type 2 diabetes. It is the…

Med Lett Drugs Ther. 2018 Jan 29; 60(1539):19-21
The FDA has approved semaglutide ( Ozempic – Novo Nordisk), a long-acting injectable GLP-1 (glucagon-like peptide-1) receptor agonist, for once-weekly treatment of adults with type 2 diabetes. It is the sixth GLP-1 receptor agonist to be approved in the US.
Issue 1529 · September 11, 2017
Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes

The FDA has approved Xultophy 100/3.6 (Novo Nordisk), a fixed-ratio combination of insulin degludec and the GLP-1 (glucagon-like peptide-1) receptor agonist liraglutide, for once-daily treatment of adults with…

Med Lett Drugs Ther. 2017 Sep 11; 59(1529):147-9
The FDA has approved Xultophy 100/3.6 (Novo Nordisk), a fixed-ratio combination of insulin degludec and the GLP-1 (glucagon-like peptide-1) receptor agonist liraglutide, for once-daily treatment of adults with type 2 diabetes inadequately controlled on basal insulin (<50 units daily) or liraglutide (≤1.8 mg daily).
Issue 1527 · August 14, 2017
Cardiovascular Effects of Some Antidiabetic Drugs

For many years, the goal of drug therapy for most patients with type 2 diabetes has been to achieve and maintain an A1C of <7%. Achieving that goal can prevent microvascular complications (diabetic…

Med Lett Drugs Ther. 2017 Aug 14; 59(1527):136-8
For many years, the goal of drug therapy for most patients with type 2 diabetes has been to achieve and maintain an A1C of <7%. Achieving that goal can prevent microvascular complications (diabetic retinopathy, nephropathy, neuropathy), but whether it prevents macrovascular complications (myocardial infarction [MI], stroke) has been less clear. The FDA now requires that cardiovascular safety studies be performed for all new drugs for type 2 diabetes.1 Recent findings that some of the newer second-line drugs for type 2 diabetes have cardiovascular benefits have led to new interest in the cardiovascular efficacy and safety of all antidiabetic drugs.
Issue 1513 · January 30, 2017
Lixisenatide for Type 2 Diabetes

The FDA has approved lixisenatide (Sanofi), a short-acting injectable GLP-1 (glucagon-like peptide-1) receptor agonist, for once-daily treatment of adults with type 2 diabetes, both alone (Adlyxin) and in a…

Med Lett Drugs Ther. 2017 Jan 30; 59(1513):19-21
The FDA has approved lixisenatide (Sanofi), a short-acting injectable GLP-1 (glucagon-like peptide-1) receptor agonist, for once-daily treatment of adults with type 2 diabetes, both alone (Adlyxin) and in a fixed-ratio combination with insulin glargine (Soliqua 100/33) . Lixisenatide has been available since 2013 in many other countries as Lyxumia . It is the fifth GLP-1 receptor agonist to be approved in the US.
Issue 1512 · January 16, 2017
Drugs for Type 2 Diabetes

The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; the target is generally an A1C of ≤7%. Treating to…

Med Lett Drugs Ther. 2017 Jan 16; 59(1512):9-18
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; the target is generally an A1C of ≤7%. Treating to this target has been shown to prevent microvascular complications (retinopathy, nephropathy, and neuropathy), but whether it prevents macrovascular outcomes is unclear. An A1C target of <8% may be appropriate for older patients and those with underlying cardiovascular disease, a history of severe hypoglycemia, diabetes-related complications or comorbidities, or a long duration of disease.
Issue 1471 · June 22, 2015
Liraglutide (Saxenda) for Weight Loss

The injectable glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide, previously approved by the FDA for treatment of type 2 diabetes as Victoza , has now also been approved at a higher dose as Saxenda…

Med Lett Drugs Ther. 2015 Jun 22; 57(1471):89-90
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide, previously approved by the FDA for treatment of type 2 diabetes as Victoza , has now also been approved at a higher dose as Saxenda (Novo Nordisk) for chronic weight management in adults with a BMI ≥30, or a BMI ≥27 with a weight-related comorbidity such as hypertension, dyslipidemia, or diabetes.
Issue 1455 · November 10, 2014
Two New GLP-1 Receptor Agonists for Diabetes

Two new injectable GLP-1 (glucagon-like peptide-1) receptor agonists, dulaglutide ( Trulicity [trū li si tee] – Lilly) and albiglutide ( Tanzeum [tan' zee um] – GSK), have been approved by the FDA for…

Med Lett Drugs Ther. 2014 Nov 10; 56(1455):109-11
Two new injectable GLP-1 (glucagon-like peptide-1) receptor agonists, dulaglutide ( Trulicity [trū li si tee] – Lilly) and albiglutide ( Tanzeum [tan' zee um] – GSK), have been approved by the FDA for once-weekly treatment of type 2 diabetes. Other available GLP-1 receptor agonists include exenatide, which is approved for injection twice daily (Byetta) or once weekly (Bydureon) , and liraglutide (Victoza) , which is injected once daily.
Issue 139 · March 1, 2014
Drugs for Type 2 Diabetes

The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal A1C concentration without inducing hypoglycemia; the target is generally an A1C of <7.0%. Treating to this target has been…

Treat Guidel Med Lett. 2014 Mar; 12(139):17-24
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal A1C concentration without inducing hypoglycemia; the target is generally an A1C of <7.0%. Treating to this target has been shown to prevent the microvascular complications of retinopathy and nephropathy, but whether it prevents macrovascular outcomes remains unclear. Three large trials found that intensive glucose control did not reduce the incidence of macrovascular events. One of these trials (ACCORD) in >10,000 patients with type 2 diabetes, with or at high-risk for cardiovascular disease, found that treating patients intensively with antihyperglycemic drugs to an A1C target of 6.0% for a mean of 3.7 years did not significantly reduce the incidence of major cardiovascular events (the primary endpoint) and was associated with increased all-cause mortality compared to patients treated to an A1C target of 7.0-7.9%. An A1C target of 7-8% may be prudent in older patients and in those with underlying cardiovascular disease, severe hypoglycemia, or multiple diabetes-related complications or co-morbidities.
Issue 1416 · May 13, 2013
Canagliflozin (Invokana) for Type 2 Diabetes

Canagliflozin (kan" a gli floe' zin; Invokana – Janssen), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been approved by the FDA for oral treatment of type 2 diabetes.

Med Lett Drugs Ther. 2013 May 13; 55(1416):37-9
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been approved by the FDA for oral treatment of type 2 diabetes.
Issue 1395 · July 23, 2012
What Comes After Metformin for Type 2 Diabetes?

Most experts agree that lifestyle modifications and metformin ( Glucophage , and others) should be used first to treat patients with type 2 diabetes. If metformin alone fails to control hyperglycemia, there is…

Med Lett Drugs Ther. 2012 Jul 23; 54(1395):58-9
Most experts agree that lifestyle modifications and metformin ( Glucophage , and others) should be used first to treat patients with type 2 diabetes. If metformin alone fails to control hyperglycemia, there is no general agreement on which drug should be added next. A recent article in The Medical Letter offered some support for a sulfonylurea. Three recent trials published in The Lancet favored the long-acting basal insulin glargine, the glucagon-like peptide (GLP-1) analog exenatide, and the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, respectively. Some of the advantages and disadvantages of these and other available agents are listed in Table 1 on the opposite page.
Issue 1386 · March 19, 2012
Extended-Release Exenatide (Bydureon) for Type 2 Diabetes

The FDA has approved a once-weekly extendedrelease formulation of exenatide ( Bydureon – Amylin), an injectable glucagon-like peptide-1 (GLP-1) receptor agonist, for treatment of type 2 diabetes.

Med Lett Drugs Ther. 2012 Mar 19; 54(1386):21-3
The FDA has approved a once-weekly extendedrelease formulation of exenatide ( Bydureon – Amylin), an injectable glucagon-like peptide-1 (GLP-1) receptor agonist, for treatment of type 2 diabetes.
Issue 108 · August 1, 2011
Drugs for Type 2 Diabetes

The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities that includes insulin resistance, diminished insulin secretion and excess hepatic glucose production.…

Treat Guidel Med Lett. 2011 Aug; 9(108):47-54
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities that includes insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet, exercise and weight loss are helpful in improving glucose control, but most patients ultimately require drug therapy.
Issue 104 · April 1, 2011
Diet, Drugs and Surgery for Weight Loss

Adults with a body mass index (BMI=kg/m 2 ) of 25-<30 are considered overweight; those with a BMI of ≥30 are considered obese.

Treat Guidel Med Lett. 2011 Apr; 9(104):17-22
Adults with a body mass index (BMI=kg/m 2 ) of 25-<30 are considered overweight; those with a BMI of ≥30 are considered obese.